BECTON DICKINSON & CO (BDX) vs JOHNSON & JOHNSON (JNJ)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BDX | JNJ |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $21.84B | $94.19B |
| Revenue growth (YoY) | ▲ 8.2% | ▲ 6.0% |
| Net income | $1.68B | $26.8B |
| Gross margin | 45.4% | 67.9% |
| Diluted EPS | $5.82 | $11.03 |
| Insider net (6 mo) | +20.2K sh • 11 sells • 0 buys | −55.1K sh • 7 sells • 0 buys |
| Institutional owners | 54 | 67 |
| Institutional value held | $26.89B | $304.18B |
| Next earnings (est.) | Around Feb 8, 2027 | Around Jan 20, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BECTON DICKINSON & CO (BDX)
Becton, Dickinson and Company (BD) is a global medical technology company, incorporated in New Jersey in 1906 as successor to a New York business started in 1897. Read more →
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson is a holding company, incorporated in New Jersey in 1887, whose operating companies research, develop, manufacture and sell a broad range of products in the healthcare field, with a primary focus on human health and well-being. Read more →
Source: SEC EDGAR.